PSAT1P2

Across TCGA pan-cancer cohorts, PSAT1P2 RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated PSAT1P2 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher PSAT1P2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSAT1P2 expression acts as an unfavorable survival marker, although some lineages such as SARC and ESCA show a favorable association.

MESO, LUSC, and READ are the cancer types where PSAT1P2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Tertile	All	0.135	0.403	.002	90	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	36	view →
READ	OS	Tertile	III,IV	0.334	0.752	.024	27	view →
SARC	DFS	Tertile	All	0.886	0.488	.002	27	view →
THCA	OS	Tertile	II,III,IV	0.276	0.901	.001	24	view →
UCEC	OS	Tertile	All	0.331	0.725	.006	24	view →
HNSC	DFS	Tertile	IV	0.205	0.587	.001	18	view →
THYM	DFS	Tertile	III,IV	0.205	0.774	.007	18	view →
ESCA	DFS	Tertile	III,IV	0.506	0.253	.017	12	view →
KIRP	DFS	Tertile	All	0.276	0.616	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

PSAT1P2–MESO (DFS)

Open the MESO breakdown →